Is increased myocardial triglyceride content associated with early changes in left ventricular function? A
cardiac magnetic resonance imaging
feature-tracking
left ventricular function
myocardial strain
myocardial triglyceride content
obesity
type 2 diabetes
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
07
03
2023
accepted:
06
06
2023
medline:
11
7
2023
pubmed:
10
7
2023
entrez:
10
7
2023
Statut:
epublish
Résumé
Type 2 diabetes (T2D) and obesity induce left ventricular (LV) dysfunction. The underlying pathophysiological mechanisms remain unclear, but myocardial triglyceride content (MTGC) could be involved. This study aimed to determine which clinical and biological factors are associated with increased MTGC and to establish whether MTGC is associated with early changes in LV function. A retrospective study was conducted using five previous prospective cohorts, leading to 338 subjects studied, including 208 well-phenotyped healthy volunteers and 130 subjects living with T2D and/or obesity. All the subjects underwent proton magnetic resonance spectroscopy and feature tracking cardiac magnetic resonance imaging to measure myocardial strain. MTGC content increased with age, body mass index (BMI), waist circumference, T2D, obesity, hypertension, and dyslipidemia, but the only independent correlate found in multivariate analysis was BMI (p=0.01; R²=0.20). MTGC was correlated to LV diastolic dysfunction, notably with the global peak early diastolic circumferential strain rate (r=-0.17, p=0.003), the global peak late diastolic circumferential strain rate (r=0.40, p<0.0001) and global peak late diastolic longitudinal strain rate (r=0.24, p<0.0001). MTGC was also correlated to systolic dysfunction Predicting MTGC remains a challenge in routine clinical practice, as only BMI independently correlates with increased MTGC. MTGC may play a role in LV dysfunction but does not appear to be involved in the development of subclinical strain abnormalities.
Sections du résumé
Background
Type 2 diabetes (T2D) and obesity induce left ventricular (LV) dysfunction. The underlying pathophysiological mechanisms remain unclear, but myocardial triglyceride content (MTGC) could be involved.
Objectives
This study aimed to determine which clinical and biological factors are associated with increased MTGC and to establish whether MTGC is associated with early changes in LV function.
Methods
A retrospective study was conducted using five previous prospective cohorts, leading to 338 subjects studied, including 208 well-phenotyped healthy volunteers and 130 subjects living with T2D and/or obesity. All the subjects underwent proton magnetic resonance spectroscopy and feature tracking cardiac magnetic resonance imaging to measure myocardial strain.
Results
MTGC content increased with age, body mass index (BMI), waist circumference, T2D, obesity, hypertension, and dyslipidemia, but the only independent correlate found in multivariate analysis was BMI (p=0.01; R²=0.20). MTGC was correlated to LV diastolic dysfunction, notably with the global peak early diastolic circumferential strain rate (r=-0.17, p=0.003), the global peak late diastolic circumferential strain rate (r=0.40, p<0.0001) and global peak late diastolic longitudinal strain rate (r=0.24, p<0.0001). MTGC was also correlated to systolic dysfunction
Conclusions
Predicting MTGC remains a challenge in routine clinical practice, as only BMI independently correlates with increased MTGC. MTGC may play a role in LV dysfunction but does not appear to be involved in the development of subclinical strain abnormalities.
Identifiants
pubmed: 37424866
doi: 10.3389/fendo.2023.1181452
pmc: PMC10323751
doi:
Substances chimiques
Triglycerides
0
Banques de données
ClinicalTrials.gov
['NCT01284816', 'NCT02042664', 'NCT03118336']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1181452Informations de copyright
Copyright © 2023 Soghomonian, Dutour, Kachenoura, Thuny, Lasbleiz, Ancel, Cristofari, Jouve, Simeoni, Kober, Bernard and Gaborit.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Circulation. 2010 Dec 14;122(24):2538-44
pubmed: 21126971
Circ Res. 2007 Oct 12;101(8):759-67
pubmed: 17932333
Endocrinology. 2003 Aug;144(8):3483-90
pubmed: 12865329
J Cardiovasc Magn Reson. 2018 Dec 24;20(1):88
pubmed: 30580760
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
J Endocrinol. 2020 Feb;244(2):249-259
pubmed: 31661671
Commun Biol. 2022 Nov 19;5(1):1271
pubmed: 36402844
Circ Cardiovasc Imaging. 2014 Dec 30;8(1):
pubmed: 25550397
Eur Heart J. 2008 Jun;29(12):1516-22
pubmed: 18492680
Am J Cardiol. 1974 Jul;34(1):29-34
pubmed: 4835750
Diabetologia. 2007 Jun;50(6):1113-5
pubmed: 17437077
Eur Heart J. 2016 Jun 1;37(21):1642-50
pubmed: 26417058
Magn Reson Med. 2011 Sep;66(3):619-24
pubmed: 21721038
Sci Rep. 2018 Feb 27;8(1):3702
pubmed: 29487372
Int J Obes (Lond). 2018 Mar;42(3):441-447
pubmed: 28974742
Am J Physiol Endocrinol Metab. 2005 Nov;289(5):E935-9
pubmed: 15972271
Hypertension. 2008 Aug;52(2):181-7
pubmed: 18574077
JACC Cardiovasc Imaging. 2015 Dec;8(12):1468-1470
pubmed: 25797124
Circ Cardiovasc Imaging. 2013 Sep;6(5):808-16
pubmed: 23833283
Metabolism. 2016 Aug;65(8):1026-37
pubmed: 26409295
Nutr Metab Cardiovasc Dis. 2016 Feb;26(2):134-40
pubmed: 26803593
J Am Coll Cardiol. 2008 Nov 25;52(22):1793-9
pubmed: 19022158
Echocardiography. 2000 Oct;17(7):653-8
pubmed: 11107201
J Am Coll Cardiol. 2010 Nov 23;56(22):1812-22
pubmed: 21087709
Eur J Heart Fail. 2017 Mar;19(3):307-313
pubmed: 27891719
J Am Coll Cardiol. 2016 Jan 5;67(1):117-9
pubmed: 26764075
J Am Coll Cardiol. 2016 Jul 5;68(1):53-63
pubmed: 27364051
Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2327-32
pubmed: 10051641
Circulation. 2018 Jul 17;138(3):305-315
pubmed: 30012703
JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 1):260-274
pubmed: 29413646
Curr Heart Fail Rep. 2021 Aug;18(4):225-239
pubmed: 33931818
Circulation. 2007 Jun 26;115(25):3213-23
pubmed: 17592090
J Vis Exp. 2011 Feb 12;(48):
pubmed: 21372778
Eur Heart J. 2018 Dec 21;39(48):4243-4254
pubmed: 30295797
Comput Biol Med. 2018 Jan 1;92:197-203
pubmed: 29227821
Tex Heart Inst J. 2012;39(2):174-8
pubmed: 22740727
JAMA. 2006 Apr 5;295(13):1549-55
pubmed: 16595758
Diabetes. 2016 Jan;65(1):44-52
pubmed: 26438611
J Cardiovasc Magn Reson. 2013 Nov 14;15:103
pubmed: 24228979
JAMA Cardiol. 2019 Mar 1;4(3):287-294
pubmed: 30810702
J Am Soc Echocardiogr. 1994 Sep-Oct;7(5):441-58
pubmed: 7986541
Compr Physiol. 2017 Jun 18;7(3):1051-1082
pubmed: 28640452
AJR Am J Roentgenol. 2020 Jul;215(1):79-86
pubmed: 32208004
Circulation. 2001 Jul 10;104(2):128-30
pubmed: 11447072
Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1784-9
pubmed: 10677535
Echocardiography. 2003 May;20(4):345-56
pubmed: 12848878
Diabetes Obes Metab. 2016 Sep;18(9):882-91
pubmed: 27106272
JACC Cardiovasc Imaging. 2015 Dec;8(12):1351-1359
pubmed: 26577264
J Infect Dis. 2020 Mar 28;221(8):1315-1320
pubmed: 31100122
J Magn Reson Imaging. 2012 Apr;35(4):804-11
pubmed: 22068959
Circulation. 2002 Apr 16;105(15):1861-70
pubmed: 11956132
J Cardiovasc Magn Reson. 2022 Nov 21;24(1):63
pubmed: 36404299
JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 1):196-205
pubmed: 28528164
J Clin Endocrinol Metab. 2009 Nov;94(11):4472-82
pubmed: 19820028
J Am Coll Cardiol. 2008 Sep 16;52(12):1006-12
pubmed: 18786482
JACC Cardiovasc Imaging. 2021 May;14(5):1038-1052
pubmed: 32828781
Heart. 2014 Nov;100(21):1673-80
pubmed: 24860005
Circ Cardiovasc Imaging. 2016 Apr;9(4):e004077
pubmed: 27009468
J Clin Endocrinol Metab. 2008 Feb;93(2):497-503
pubmed: 18029455
JACC Cardiovasc Imaging. 2020 Apr;13(4):948-950
pubmed: 31954649
Diabetes. 2007 Dec;56(12):2849-53
pubmed: 17717279
Circulation. 2007 Sep 4;116(10):1170-5
pubmed: 17698735
Eur Heart J Cardiovasc Imaging. 2015 Aug;16(8):871-81
pubmed: 25711353
Magn Reson Med. 2003 Mar;49(3):417-23
pubmed: 12594743
Cardiovasc Diabetol. 2020 May 29;19(1):70
pubmed: 32471503
N Engl J Med. 2002 Aug 1;347(5):305-13
pubmed: 12151467
Cardiovasc Diabetol. 2021 Mar 1;20(1):57
pubmed: 33648515
Eur Radiol. 2019 Dec;29(12):6846-6857
pubmed: 31297633
EBioMedicine. 2021 Dec;74:103735
pubmed: 34864619
J Am Coll Cardiol. 2010 Jan 26;55(4):283-93
pubmed: 20117431
Biochim Biophys Acta. 2016 Oct;1861(10):1555-68
pubmed: 26899197
Int J Obes (Lond). 2012 Mar;36(3):422-30
pubmed: 21730964
Eur Heart J. 2019 Oct 21;40(40):3297-3317
pubmed: 31504452
Heart Fail Clin. 2021 Jul;17(3):345-356
pubmed: 34051967
J Am Coll Cardiol. 2012 Oct 9;60(15):1381-9
pubmed: 22939560
Diabetologia. 2005 Jun;48(6):1229-37
pubmed: 15864533